Добро пожаловать в клуб

Показать / Спрятать  Домой  Новости Статьи Файлы Форум Web ссылки F.A.Q. Логобург    Показать / Спрятать

       
Поиск   
Главное меню
ДомойНовостиСтатьиПостановка звуковФайлыДефектологияКнижный мирФорумСловарьРассылкаКаталог ссылокРейтинг пользователейЧаВо(FAQ)КонкурсWeb магазинШкольникамКарта сайта

Поздравляем!
Поздравляем нового Логобуржца мари25 со вступлением в клуб!

Реклама

КНИЖНЫЙ МИР

Current status of glycopeptides resistance among MRSA isolates   Fatima Kaleem

Current status of glycopeptides resistance among MRSA isolates

132 страниц. 2010 год.
LAP Lambert Academic Publishing
Vancomycin has been widely used in the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The emergence of vancomycin-intermediate and vancomycin resistant Staphylococcus aureus (VISA and VRSA, respectively) in various parts of the world has been of great concern in clinical settings. This study was performed to monitor the status of vancomycin susceptibility against MRSA in our set up. All non duplicate MRSA isolates recovered from various wards of Military Hospital Rawalpindi were subjected to the detection of minimum inhibitory concentrations (MICs) of vancomycin using E- strips. Isolates having standard vancomycin MICs equal or greater than 1 ug/ mL were subjected to the detection of Glycopeptide Intermediate Staphylococcus aureus (GISA) / heterogeneous Glycopeptide Intermediate Staphylococcus aureus (h GISA) by using GRD (Glycopeptide Resistance Detection) E- Test. Results were analyzed to evaluate the possible presence of ...
 
- Генерация страницы: 0.06 секунд -